BRAF and melanoma: A subgroup analysis from CheckMate-067 demonstrated that the absolute difference in 5-year overall survival was substantially greater for the combination than nivolumab alone in patients with BRAF-mutant melanoma (60% ipilimumab plus nivolumab vs. 46% nivolumab alone).